MindMed's new Chief Development Officer has over a decade of experience leading drug development programs.
Exploring the companies and themes that make up this emerging and exciting new sector
Mydecine Innovations Group Upsizes Previously Announced Bought Deal
Mydecine's bought-deal financing is upsized by 50% to CAD $15 million.
Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units
Mydecine announces a bought-deal financing with units priced at CAD$0.50.
Novamind Expands Psychedelic Medicine Access in Utah
Novamind Inc announces the expansion and optimization of its Cedar Psychiatry clinic in Utah.
This is Why the Psilocybin Story is Quickly Gaining Momentum
Clinical studies continue to support the use of psilocybin for mental health. For example, a study from JAMA Psychiatry found that psilocybin “worked better than the usual antidepressant medications,” as noted by NPR.
Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy
MindCure signs LOI to make a strategic investment in ATMA, a psychedelics-assisted therapy center in Calgary, Alberta.
Cybin Announces API Synthesis of Multiple Tryptamine Derivatives Based on the First Milestone Achievement Pursuant to the Adelia Acquisition
Cybin announces the API synthesis of multiple tryptamine derivatives.
Core One Labs Announces Breakthrough in Solving Psilocybin Dosing Problems by Introducing Biosynthetic Psilocybin to its Patented Thinstrip Delivery Method
Core One Labs announces a research breakthrough to help improve consistency in psilocybin dosing.
MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers
MindMed commences LSD microdosing study on various health-and-wellness benefits.
Michigan Prosecutor Won’t Pursue Most Marijuana Or Psychedelics Cases, ‘Regardless Of The Amount’
A county prosecutor in Michigan announced on Tuesday that his office will not be pursuing charges over possessing marijuana or entheogenic substances like psilocybin and ayahuasca — “regardless of the amount at issue.”
ATAI or MindMed: Which Is The Better Opportunity?
ATAI Life Sciences and MindMed Inc have the deepest psychedelics operations in this sector. Which is the better opportunity?
MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers
MindMed to Commence Groundbreaking LSD Microdosing Study Evaluating Benefits on Neuroplasticity, Sleep, Cognitive Enhancement Variables and Immune System Response on the Human Body